In cancer, deregulation of the individual CDKs is linked to different tumor types with high levels of CDK4 being common in sarcoma, glioma and melanoma [14–16] whereas overexpression of CDK6 is more frequent in hematologic malignancies [17, 18]. Here, CDK6 is linked to hematologic disorder.